Molecular monitoring of residual disease using antigen receptor genes in childhood acute lymphoblastic leukaemia

Best Practice and Research: Clinical Haematology

Volumn 15, Issue 1, 2002, Pages 37-57

  Szczepański, Tomasz ^a   Flohr, Thomas ^b   Van Der Velden, Vincent H J ^a   Bartram, Claus R ^b   Van Dongen, Jacques J M ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Acute lymphoblastic leukaemia (ALL); Childhood ALL; Ig heavy chain genes (IGH); Ig kappa light chain genes (IGK); Immunoglobulin (Ig) and T cell receptor (TCR) gene rearrangements; LightCycler based RQ PCR; Minimal residual disease (MRD); Polymerase chain reaction (PCR); Real time quantitative PCR (RQ PCR); TaqMan based RQ PCR; TCR delta genes (TCRD); TCR gamma genes (TCRG)

Indexed keywords

ANTINEOPLASTIC AGENT; IMMUNOGLOBULIN; LYMPHOCYTE ANTIGEN RECEPTOR; PREDNISONE; T LYMPHOCYTE RECEPTOR; DNA;

ACUTE LYMPHOBLASTIC LEUKEMIA; ARTICLE; CHILD; CHILDHOOD LEUKEMIA; CONTROLLED STUDY; DNA FINGERPRINTING; DRUG SENSITIVITY; FOLLOW UP; GENE REARRANGEMENT; GENE SEQUENCE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; LABORATORY DIAGNOSIS; LEUKEMIA REMISSION; MINIMAL RESIDUAL DISEASE; MOLECULAR CLONING; PATIENT MONITORING; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROGNOSIS; RECURRENCE RISK; SENSITIVITY ANALYSIS; T LYMPHOCYTE RECEPTOR GENE; TREATMENT OUTCOME; BONE MARROW TRANSPLANTATION; CLONAL VARIATION; HIGH RISK POPULATION; LEUKEMIA RELAPSE; MONITORING; REVIEW; STEM CELL TRANSPLANTATION; ACUTE LYMPHOCYTIC LEUKEMIA; GENETICS; IMMUNOGLOBULIN GENE; IMMUNOLOGY;

CHILD; DNA, NEOPLASM; GENE REARRANGEMENT; GENES, IMMUNOGLOBULIN; GENES, T-CELL RECEPTOR; HUMANS; LEUKEMIA, LYMPHOCYTIC, ACUTE, L1; NEOPLASM, RESIDUAL; PROGNOSIS;

EID: 0036009608     PISSN: 15216926     EISSN: None     Source Type: Journal    
DOI: 10.1053/beha.2002.0184     Document Type: Article

References (100)

1. Long-term results of large prospective trials in childhood acute lymphoblastic leukemia
2. Somatic generation of antibody diversity
3. T-cell antigen receptor genes and T-cell recognition
4. Analysis of immunoglobulin and T cell receptor genes. Part I: Basic and technical aspects
5. Immunobiology of leukemia
6. In vitro amplification of T cell gamma gene rearrangements: A new tool for the assessment of minimal residual disease in acute lymphoblastic leukemias
7. Detection of minimal residual disease in acute lymphoblastic leukemia by in vitro amplification of rearranged T-cell receptor delta chain sequences
8. Minimal residual disease in childhood B-lineage lymphoblastic leukemia. Persistence of leukemic cells during the first 18 months of treatment
9. Southern blot patterns, frequencies and junctional diversity of T-cell receptor δ gene rearrangements in acute lymphoblastic leukemia
10. The complete nucleotide sequence of the human immunoglobulin heavy chain variable region locus
11. Precursor-B-ALL with DH-JH gene rearrangements have an immature immunogenotype with a high frequency of oligoclonality and hyperdiploidy of chromosome 14
12. Primers and protocols for standardized MRD detection in ALL using immunoglobulin and T cell receptor gene arrangements and TALI deletions Action: Investigation of minimal residual disease in acute leukemia
13. Characterization of clone-specific rearranged T-cell receptor gamma-chain genes in lymphomas and leukemias by the polymerase chain reaction and DNA sequencing
14. Detection of clonal immunoglobulin gene rearrangements by polymerase chain reaction amplification and single-strand conformational polymorphism analysis
15. Rapid, nonradioactive detection of clonal T-cell receptor gene rearrangements in lymphoid neoplasms
16. Heteroduplex analysis of T-cell receptor gamma gene rearrangements for diagnosis and monitoring of cutaneous T-cell lymphomas
17. Heteroduplex PCR analysis of rearranged T cell receptor genes for clonality assessment in suspect T cell proliferations
18. Identification and structural analysis of rearranged immunoglobulin heavy chain genes in lymphomas and leukemias
19. Immunoglobulin gene 'fingerprinting': An approach to analysis of B lymphoid clonality in lymphoproliferative disorders
20. Analysis of rearranged T-cell receptor beta-chain genes by polymerase chain reaction (PCR) DNA sequencing and automated high resolution PCR fragment analysis
21. Analysis of immunoglobulin and T cell receptor genes. Part II: Possibilities and limitations in the diagnosis and management of lymphoproliferative diseases and related disorders
22. Detection of immunoglobulin kappa light-chain gene rearrangement patterns by Southern blot analysis
23. Multiple rearranged immunoglobulin genes in childhood acute lymphoblastic leukemia of precursor B-cell origin
24. Immunoglobulin lambda isotype gene rearrangements in B-cell malignancies
25. A uniform deleting element mediates the loss of kappa genes in human B cells
26. Immunoglobulin kappa gene rearrangements between the kappa deleting element and Jkappa recombination signal sequences in acute lymphoblastic leukemia and normal hematopoiesis
27. T cell receptor alpha-, beta-, and gamma-genes in T-cell and pre-B cell acute lymphoblastic leukemia
28. Cross-lineage T-cell receptor gene rearrangements occur in more than ninety percent of childhood precursor-B-acute lymphoblastic leukemias: Alternative PCR targets for detection of minimal residual disease
29. + T cell acute lymphoblastic leukemia
30. Two consecutive immunophenotypic switches in a child with immunogenotypically stable acute leukaemia
31. T-cell receptor delta gene recombination in common acute lymphoblastic leukemia: Preferential usage of V delta 2 and frequent involvement of the J alpha cluster
32. Frequent ongoing T-cell receptor rearrangements in childhood B-precursor acute lymphoblastic leukemia: Implications for monitoring minimal residual disease
33. Immunoglobulin and T cell receptor gene rearrangement patterns in acute lymphoblastic leukemia are less mature in adults than in children: Implications for selection of PCR targets for detection of minimal residual disease
34. The incidence of clonal T-cell receptor rearrangements in B-cell precursor acute lymphoblastic leukemia varies with age and genotype
35. Heterogeneity in junctional regions of immunoglobulin kappa deleting element rearrangements in B cell leukemias: A new molecular target for detection of minimal residual disease
36. Development of human T lymphocytes and their thymus-dependency
37. T cell receptor gamma (TCRG) gene rearrangements in T cell acute lymphoblastic leukemia reflect 'end stage' recombinations: Implications for minimal residual disease monitoring
38. Ig heavy chain gene rearrangements in T-cell acute lymphoblastic leukemia exhibit predominant DH6-19 and DH7-27 gene usage, can result in complete V-D-J rearrangements, and are rare in T-cell receptor αβ lineage
39. Detection of minimal residual leukemia by the polymerase chain reaction: Potential implications for therapy
40. Minimal residual disease in leukaemia patients
41. T lymphocytes in bone marrow samples of children with acute lymphoblastic leukemia during and after chemotherapy might hamper PCR-based minimal residual disease studies
42. Regenerating normal B-cell precursors during and after treatment of acute lymphoblastic leukaemia: Implications for monitoring of minimal residual disease
43. Regeneration pattern of precursor-B-cells in bone marrow of acute lymphoblastic leukemia patients depends on the type of preceding chemotherapy
44. Quantitation of targets for PCR by use of limiting dilution
45. Accurate quantitation of residual B-precursor acute lymphoblastic leukemia by limiting dilution and a PCR-based detection system: A description of the method and the principles involved
46. Prospective monitoring and quantitation of residual blasts in childhood acute lymphoblastic leukemia by polymerase chain reaction study of delta and gamma T-cell receptor genes
47. Polymerase chain reaction, real-time quantitative
48. Real time quantitative PCR
49. Detection of specific polymerase chain reaction product by utilizing the 5′-3′ exonuclease activity of Thermus aquaticus DNA polymerase
50. Real-time quantitative PCR for the detection of minimal residual disease in acute lymphoblastic leukemia using junctional regions specific TaqMan probes
51. Application of germline IGH probes in real-time quantitative PCR for the detection of minimal residual disease in acute lymphoblastic leukemia
52. Improved assessment of minimal residual disease in B cell malignancies using fluorogenic consensus probes for real-time quantitative PCR
53. Potential of LightCycler technology for quantification of minimal residual disease in childhood acute lymphoblastic leukemia
54. Rapid and reliable quantification of minimal residual disease in acute lymphoblastic leukemia using rearranged immunoglobulin and T-cell receptor loci by LightCycler technology
55. Unusual immunoglobulin and T-cell receptor gene rearrangement patterns in acute lymphoblastic leukemias
56. Continuing rearrangement but absence of somatic hypermutation in immunoglobulin genes of human B cell precursor leukemia
57. Immunoglobulin heavy chain gene VH-D junctional diversity at diagnosis in patients with acute lymphoblastic leukemia
58. A polymerase chain reaction study of the stability of Ig heavy-chain and T-cell receptor delta gene rearrangements between presentation and relapse of childhood B-lineage acute lymphoblastic leukemia
59. Differences in immunoglobulin heavy chain gene rearrangement patterns between bone marrow and blood samples in childhood precursor B-acute lymphoblastic leukemia at diagnosis
60. Analysis of Ig and T-cell receptor genes in 40 childhood acute lymphoblastic leukemias at diagnosis and subsequent relapse: Implications for the detection of minimal residual disease by polymerase chain reaction analysis
61. Heterogeneity of the T-cell receptor delta gene indicating subclone formation in acute precursor B-cell leukemias
62. Characterisation of non-concordance in the T-cell receptor gamma chain genes at presentation and clinical relapse in acute lymphoblastic leukemia
63. Quantification of minimal residual disease in children with oligoclonal B-precursor acute lymphoblastic leukemia indicates that the clones that during induction therapy
64. Clonal stability in children with acute lymphoblastic leukemia (ALL) who relapsed five or more years after diagnosis
65. Prognostic value of minimal residual disease in acute lymphoblastic leukaemia in childhood
66. Use of polymerase chain reactions to monitor minimal residual disease in acute lymphoblastic leukemia patients
67. Detection of minimal residual disease in T-cell acute lymphoblastic leukemia using polymerase chain reaction predicts impending relapse
68. Residual disease at the end of induction therapy as a predictor of relapse during therapy in childhood B-lineage acute lymphoblastic leukemia
69. Minimal residual disease in childhood acute lymphoblastic leukemia: Analysis of patients in continuous complete remission or with consecutive relapse
70. Molecular residual disease status at the end of chemotherapy fails to predict subsequent relapse in children with B-lineage acute lymphoblastic leukemia
71. Long-term follow-up of residual disease in acute lymphoblastic leukemia patients in complete remission using clonogeneic IgH probes and the polymerase chain reaction
72. Outcome prediction in childhood acute lymphoblastic leukaemia by molecular quantification of residual disease at the end of induction
73. Prolonged persistence of PCR-detectable minimal residual disease after diagnosis or first relapse predicts poor outcome in childhood B-precursor acute lymphoblastic leukemia
74. Prospective monitoring of minimal residual disease during the course of chemotherapy in patients with acute lymphoblastic leukemia, and detection of contaminating tumor cells in peripheral blood stem cells for autotransplantation
75. Measurement of residual leukemia during remission in childhood acute lymphoblastic leukemia
76. Detectable molecular residual disease at the beginning of maintenance therapy indicates poor outcome in children with T-cell acute lymphoblastic leukemia
77. Minimal residual disease after intensive induction therapy in childhood acute lymphoblastic leukemia predicts outcome
78. Minimal residual disease analysis for the prediction of relapse in children with standard-risk acute lymphoblastic leukaemia
79. Residual disease detection using fluorescent polymerase chain reaction at 20 weeks of therapy predicts clinical outcome in childhood acute lymphoblastic leukemia
80. Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia
81. Immunological detection of minimal residual disease in children with acute lymphoblastic leukaemia
82. A prospective study of minimal residual disease in childhood B-lineage acute lymphoblastic leukaemia: MRD level at the end of induction is a strong predictive factor of relapse
83. Rapid molecular response during early induction chemotherapy predicts a good outcome in childhood acute lymphoblastic leukemia
84. Molecular detection of minimal residual disease is a strong predictive factor of relapse in childhood B-lineage acute lymphoblastic leukemia with medium risk features
85. Corticosteroid-dependent reduction of leukocyte count in blood as a prognostic factor in acute lymphoblastic leukemia in childhood (therapy study ALL-BFM 83)
86. Investigation of minimal residual disease in childhood and adult acute lymphoblastic leukaemia by molecular analysis
87. Outcome of treatment in children with Philadelphia chromosome-positive acute lymphoblastic leukemia
88. Effect of the Philadelphia chromosome on minimal residual disease in acute lymphoblastic leukemia
89. A prospective study of residual-disease monitoring of the ALL1/AF4 transcript in patients with t(4;11) acute lymphoblastic leukemia
90. Intensified therapy for infants with acute lymphoblastic leukemia: Results from the Dana-Farber Cancer Institute Consortium
91. Minimal residual disease studies are beneficial in the follow-up of TEL/AMLI patients with B-precursor acute lymphoblastic leukaemia
92. Treatment of acute lymphoblastic leukemia. 30 years' experience at St Jude Children's Research Hospital
93. MRD at the end of induction therapy in childhood acute lymphoblastic leukemia: Outcome prediction strongly depends on the therapeutic regimen
94. Prognostic value of minimal residual disease in relapsed childhood acute lymphoblastic leukaemia
95. Minimal residual disease status before allogeneic bone marrow transplantation is an important determinant of successful outcome for children and adolescents with acute lymphoblastic leukemia
96. Impact of minimal residual disease prior to allogeneic stem cell transplantation in children with ALL
97. Real-time quantitative PCR for detection of minimal residual disease before allogeneic stem cell transplantation predicts outcome in children with acute lymphoblastic leukemia
98. Minimal residual disease status as a predictor of relapse after allogeneic bone marrow transplantation for children with acute lymphoblastic leukaemia
99. Monitoring minimal residual disease in peripheral blood in B-lineage acute lymphoblastic leukaemia
100. Minimal residual disease in childhood acute lymphoblastic leukaemia quantified by aspirate and trephine: Is the disease multifocal?